Overview
This randomized, controlled, open-label, parallel, multicenter clinical study evaluates the efficacy of SmartSignalHF compared with heart failure (HF) remote monitoring (RM) standard of care in implanted patients with heart failure. The primary objective is to determine whether SmartSignalHF reduces all-cause mortality and HF hospitalizations at 12 months.
Description
SmartSignalHF is a novel digital health solution designed to support clinical decision-making by continuously analyzing Cardiac Implantable Electronic Devices (CIED) and patient data and providing actionable alerts to healthcare teams. By integrating this digital solution into the remote monitoring of HF patients, the study aims to enhance early detection of decompensation events and optimize therapeutic treatments.
Eligible patients implanted with an Implantable Cardioverter Defibrillator (ICD) or a Cardiac Resynchronization Therapy Defibrillator (CRT-D) and diagnosed with chronic heart failure will be randomized in a 1:1 ratio to either SmartSignalHF remote monitoring solution or standard HF remote monitoring solution.
The primary endpoint is a composite of all-cause mortality and HF hospitalizations within 12 months after randomization. Secondary endpoints include individual components of the primary endpoint, quality-of-life measures, and adherence to guideline-directed medical therapy (GDMT).
Eligibility
Inclusion Criteria:
- Patient aged 18-85
- Patient diagnosed with a New York Heart Association (NYHA) class II or III
- Patients with left ventricular ejection fraction ≼ 40 %
- Patient implanted with an ICD or CRT-D (BiV and/or LBBA pacing) since at least 30 days and compatible with SignalHF (Biotronik, Boston Scientific and Medtronic)
- Non-activation of others HF multisensor algorithms
- Patient remote monitored on Implicity CIED platform
- Patient with a documented diagnosis of heart failure, eligible to reimbursement in France or Germany for HF remote monitoring
- Patient is willing to be remotely monitored for heart failure
- HF treated according to European Society of Cardiology (ESC) guidelines
Exclusion Criteria:
- Patients undergoing or awaiting heart transplant or left ventricular assist device (LVAD) procedures
- Patients with a life expectancy of less than 12 months
- Patients enrolled in concurrent clinical studies
- Patients with a history of non-compliance with medical care or inability to comply with the study protocol
- Patients already receiving remote monitoring for heart failure
- Pregnant or breastfeeding women
- Subjects under legal protection
